Home > Resources > Company Profiles > Eli Lilly & Company

Eli Lilly & Company (LLY)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Enter the text you see in the image *

Letters are not case-sensitive, disregard spaces.

Try a New One

This helps us prevent automated registrations and spamming.

Email Confirmation

Dr. John C. Lechleiter, Ph.D. , President/COO/Director/CEO

www.lilly.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

The Company discovers, develops, manufactures and sells products in one segment of pharmaceutical products.

Press Releases

Sucampo Pharmaceuticals Appoints Andrew J. Ferrara to its Board of Directors Jul-22-2008, 08:00AM EDT
The ED Conversation Dilemma: Forty Percent of Men with ED Don't Talk to Their Doctor, Survey Finds Jul-16-2008, 08:00AM EDT
Lilly Partners With the National Council of La Raza to Fight Chronic Disease Jul-13-2008, 09:00AM EDT
Lilly Supports Industry Code on Interactions with Healthcare Professionals Jul-10-2008, 09:00AM EDT
Enlight Biosciences Launched in Collaboration with Merck & Co., Inc., Pfizer, and Eli Lilly Jul-10-2008, 07:30AM EDT

News From Around the Web

News

Eli Lilly profit increases 44 percent in 2nd qtr on rising sales, but cuts profit forecast (Newsday)

Jul 24 2008
Mixed Start May Await Stocks on Wall Street (The Street)

Jul 24 2008
Eli Lilly profit increases 44 percent in 2nd qtr on rising sales; but cuts profit forecast (Baltimore Sun)

Jul 24 2008
Eli Lilly Q2 profit increases; matches estimates - Quick Facts 1 (RTTNews)

Jul 24 2008
Earnings Preview: Eli Lilly & Co. (SeekingAlpha)

Jul 23 2008
7 Dividend Stocks for a Bear Market (Motley Fool)

Jul 22 2008
Pfizer, AstraZeneca, Merck, Eli Lilly, and Others Explain Their Strategies in Storing and Supplying Compounds (PharmaLive)

Jul 22 2008
CORRECTED - UPDATE 1-Amylin posts wider second-quarter net loss (Reuters)

Jul 22 2008
SGX Pharm Hldrs To Vote Aug 20 On Eli Lilly Deal >SGXP LLY (Wall Street Journal)

Jul 22 2008

Blogs

Is Pfizer's Viagra "Sagging" With The Economy? (CNBC: Pharmas Market with Mike Huckman)

Jul 23 2008

Employees

Number of Employees: 40,600

Revenue per Employee: $426,246

Top Executives

Robert A. Armitage, Senior VP/General Counsel

Bryce D. Carmine, Executive VP, Divisional

Alex M. Azar, II, Senior VP, Divisional

Dr. Steven M. Paul, M.D., Executive VP, Divisional

Derica W. Rice, CFO/Senior VP

Arnold C. Hanish, Chief Accounting Officer

Gino Santini, Divisional Senior VP

Anthony J. Murphy, Ph.D., Divisional Senior VP

Frank M. Deane, Ph.D., President, Divisional

Scott A. Canute, Divisional President

Deirdre P. Connelly, Divisional President

Board of Directors

Michael L. Eskew, Director

Dr. Franklyn G. Prendergast, M.D., Ph.D., Director

Dr.Karen N. Horn, Ph.D., Director

Dr.Alfred G. Gilman, M.D., Ph.D., Director

Sidney Taurel, Chairman of the Board/Director

George M. C. Fisher, Director

Kathi P. Seifert, Director

Ellen R. Marram, Director

J. Erik Fyrwald, Director

Dr.Martin S. Feldstein, Ph.D., Director

J. Michael Cook, Director

Sir Winfried F. W. Bischoff, Director

Financials

Quarterly

Annual

Income Statement	04/2008	01/2008	10/2007	08/2007
Sales	1.11 Bil.	1.27 Bil.	789.1 Mil.	736.4 Mil.
Gross Operating Profit	3.7 Bil.	3.92 Bil.	3.8 Bil.	3.89 Bil.
Operating Income before D & A (EBITDA)	1.27 Bil.	1.21 Bil.	1.48 Bil.	1.52 Bil.
Total Income Before Interest Expenses (EBIT)	1.06 Bil.	1.14 Bil.	1.23 Bil.	985.8 Mil.
Total Net Income	1.06 Bil.	854.4 Mil.	926.3 Mil.	663.6 Mil.
Basic EPS, Total	0.97	0.78	0.85	0.61
Diluted EPS, Total	0.97	0.78	0.85	0.61

BALANCE STATEMENT	04/2008	01/2008	10/2007	08/2007
Cash and Equivalents	NA	NA	2.5 Bil.	2.22 Bil.
Total Assets	NA	NA	10.45 Bil.	9.56 Bil.
Total Liabilities	NA	NA	4.07 Bil.	4.55 Bil.
Total Capitalization	NA	NA	17.48 Bil.	16.13 Bil.

Cash Flow	04/2008	01/2008	10/2007	08/2007
Net Cash From Continuing Operations	NA	NA	2.92 Bil.	1.48 Bil.
Net Cash From Investing Activities	NA	NA	-3.26 Bil.	-2.61 Bil.
Net Cash From Financing Activities	NA	NA	-354.2 Mil.	219 Mil.
Net Change in Cash & Cash Equivalents	NA	NA	-613.8 Mil.	-888.8 Mil.

Income Statement	2008	2007	2006	2005
Sales	4.25 Bil.	2.74 Bil.	2.75 Bil.	2.63 Bil.
Gross Operating Profit	14.38 Bil.	12.95 Bil.	11.9 Bil.	11.23 Bil.
Operating Income before D & A (EBITDA)	4.8 Bil.	4.93 Bil.	4.38 Bil.	4.26 Bil.
Total Income Before Interest Expenses (EBIT)	3.89 Bil.	3.66 Bil.	2.82 Bil.	2.99 Bil.
Total Net Income	295.3 Bil.	2.66 Bil.	1.98 Bil.	1.81 Bil.
Basic EPS, Total	2.71	2.45	1.82	1.67
Diluted EPS, Total	2.71	2.45	1.81	1.66

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	NA	3.11 Bil.	3.01 Bil.	5.37 Bil.
Total Assets	NA	9.69 Bil.	10.8 Bil.	12.84 Bil.
Total Liabilities	NA	5.09 Bil.	5.72 Bil.	7.59 Bil.
Total Capitalization	NA	14.48 Bil.	16.56 Bil.	15.41 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	3.98 Bil.	1.91 Bil.	2.87 Bil.
Net Cash From Investing Activities	NA	608.4 Mil.	-2.22 Bil.	-684.8 Mil.
Net Cash From Financing Activities	NA	-4.58 Bil.	-1.88 Bil.	203.7 Mil.
Net Change in Cash & Cash Equivalents	NA	102.6 Mil.	-2.36 Bil.	2.61 Bil.

Eli Lilly & Company (LLY)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request